Polaris Group recently announced that the U.S. Food & Drug Administration (FDA) has approved the company's Special Protocol Assessment (SPA) for a Phase 3 clinical trial of pegylated arginine deiminase (ADI-PEG 20) directed towards patients with advanced hepatocellular carcinoma (HCC) who have not responded to other treatments.
During the Phase 2 clinical trials it was found that other cancers have been reported to have responded. Early-to-mid-stage clinical showed positive results in patients with metastatic melanoma, and Phase 2 trials for small cell lung cancer (SCLC) and mesothelioma are continuing.
There are quite a few resources on the Internet to learn more about mesothelioma symptoms as well as other new cancer treatments on the horizon.
No comments:
Post a Comment